ArticleNature communications2025
Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Immunosuppressive Pathways in Cutaneous Melanoma: Functional Integration Between PD-1 and CD73 and Therapeutic Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The genome takes the wheel: CAR T with built-in circuits.Immuno-oncology technology · 2026Article
- Nucleotide signaling in neutrophils: a key player in cancer dynamics.Purinergic signalling · 2026Review
- Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8Nature immunology · 2026Article
- High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion.Nature communications · 2026Article
- CAR-T in the Treatment of Solid Tumors-A Review of Current Research and Future Perspectives.International journal of molecular sciences · 2025Review
- Article
- Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation.Frontiers in immunology · 2025Review
- Above and beyond senescence and CAR T cell: advances and future perspectives.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Kevin Sek *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. kevin.sek@petermac.org.ORCID http://orcid.org/0000-0003-4634-7600
Amanda X Y Chen *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Thomas ColeCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Jesse D ArmitageUniversity of Western Australia, Perth, WA, Australia.
Junming TongCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0006-6454-8704
Kah Min YapCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-5009-9895
Isabelle MunozCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-6510-5696
Phoebe A DunbarCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Shiyi WuCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Marit J van ElsasCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Olivia HidajatCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Christina SchefflerCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-3731-6204
Lauren GiuffridaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Melissa A HendersonCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Deborah MeyranCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-2723-8185
Fernando Souza-Fonseca-GuimaraesFrazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia.ORCID http://orcid.org/0000-0002-2037-8946
Dat NguyenCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Yu-Kuan HuangCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-2262-7069
Maria N de MenezesCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-3231-0620
Emily B DerrickCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-7191-3948
Cheok Weng ChanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Kirsten L ToddCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-3903-166X
Jack D ChanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-5942-8592
Jasmine LiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Junyun LaiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Emma V PetleyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sherly MardianaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Anthony BoscoAsthma and Airway Disease Research Center, The University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-4335-615X
Jason WaithmanUniversity of Western Australia, Perth, WA, Australia.
Ian A ParishCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-3528-478X
Christina MølckSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
Gregory D StewartDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-9748-4990
Lev KatsSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-8742-8138
Imran G HouseCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-6245-5954
Phillip K DarcyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. phil.darcy@petermac.org.ORCID http://orcid.org/0000-0002-5303-9561
Paul A BeavisCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. paul.beavis@petermac.org.ORCID http://orcid.org/0000-0002-2116-013X
Funding
Cancer Council Victoria 836379
Abstract
The efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A
Indexed as
Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorCRISPR-Cas SystemsFemaleHumansMiceMice, Inbred C57BLReceptor, Adenosine A2ATumor MicroenvironmentReceptor, Adenosine A2AReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.